OpGen (OPGN) Stock Price

OpGen Price

NASDAQ·CLOSED
3.14
​
Market closed

Revenue has compounded at 13.5% per year over the past 13 years to 30.20 M USD. OpGen's net margin stands at 78.2%, up from -808.3% several years earlier. Analysts set a median price target of 3.06 USD, implying 2.5% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

OpGen stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen business model & stock analysis

OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information.

Frequently asked questions about OpGen

Analysts currently set an average price target of 3.06 USD for the OpGen stock (median: 3.06 USD), implying -2.5 % versus the latest price. The consensus is based on 7 analyst ratings.

6 analysts currently rate the OpGen stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the OpGen share trades at 2.79 EUR (3.14 USD).

The OpGen share (OPGN) is listed on 5 stock exchanges, including: NASDAQ (OPGN), London (0A8L.L), Frankfurt (6502.F), München (6502.MU), Düsseldorf (6502.DU).

The revenue cannot currently be calculated for OpGen.

The profit cannot currently be calculated for OpGen.

The P/E ratio cannot be calculated for OpGen at the moment.

The P/S cannot be calculated for OpGen currently.

The Eulerpool Quality Score for OpGen is 6/10.

The ISIN of OpGen is US68373L5057. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OpGen is A2PQ6B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OpGen is OPGN. The ticker symbol is used to trade OpGen shares on the stock exchange.

Fair ValueTerminal
2.92 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
10.07 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website opgen.com
Currency
USD
Initial public offering
May 5, 2015
ISIN
US68373L5057
Cusip
68373L307
Sedol
BHNWR66
Market capitalization
31.87 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
1.38
P/B Ratio
1.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
70.08 %
Last updated Oct 19, 2026, 12:48 AM

OpGen Ticker

DÜSSELDORF · 6502.DUFRANKFURT · 6502.FLONDON · 0A8L.LMUNICH · 6502.MUNASDAQ · OPGN

All fundamentals and in-depth analysis of OpGen

Our stock analysis for OpGen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OpGen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.